Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm Multicenter Open-label Phase II Clinical Study of the Combination of Rituximab Chidamide Zanubrutinib-induced and CHOP Therapy for Untreated Dual-expressing Diffuse Large B Cell Lymphoma

Next Previous
Trial Profile

A Single-arm Multicenter Open-label Phase II Clinical Study of the Combination of Rituximab Chidamide Zanubrutinib-induced and CHOP Therapy for Untreated Dual-expressing Diffuse Large B Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Pirarubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Tucidinostat (Primary) ; Vincristine (Primary) ; Zanubrutinib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results (n=34) assessing safety and efficacy of Rituximab, chidamide, and zanubrutinib (ZCR) CHOP as a regimen for treatment naive (TN) double-expressor DLBCL presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 22 Apr 2023 Status changed from not yet recruiting to recruiting.
  • 08 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top